Stefan Gazdoiu

Stefan Gazdoiu is a seasoned professional in the oncology field, currently serving as a Senior Medical Science Liaison at Recordati Rare Diseases Inc., focusing on SYLVANT for multicentric Castleman’s disease. Previously, Stefan held senior roles at MacroGenics and Y-mAbs Therapeutics, contributing to MARGENZA and DANAYELZA, respectively. At Novartis Oncology, Stefan supported the launch of seven cancer treatments and established vital relationships with healthcare professionals. With a diverse background in medical science liaison roles and experience in business development and research, Stefan has a PhD from Icahn School of Medicine and an MBA from Vlerick Business School. Continuing professional education includes an Immuno-oncology certificate from Harvard Medical School.